Table 2 Studies included in the final analysis
Author and Year | Location | Study type | Study period | Number of centers | Number of participants | Median age (years) | Gender ratio (m:f) | max. ECOG | Location of cancer (% head) | Previous CTx (%) | Previous RTx (%) | SBRT BED 2;10 (Gy) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cozzi (2019) | Italy | retrospective data analysis | n/a | 1 | 100 | 70.5 | 47:53 | 2 | 65.0 | 55 | 0 | 65.63 |
Gurka (2013) | USA | prospective clinical trial phase I | 2009–2011 | 1 | 11 | 62.5 | 05:05 | 1 | 80.0 | 100 | 0 | 31.25 |
Herman (2015), Rao (2016) | USA | prospective clinical trial phase II | 2010–2012 | 3 | 60 | 67 | 31:18 | 1 | 84.0 | 90 | 0 | 45.65 |
Hoyer (2005) | Denmark | prospective clinical trial phase II | 2000–2001 | 2 | 22 | 61 | 10:12 | 2 | n/a | 0 | 0 | 93.75 |
Ji (2020) | China | retrospective data analysis | 2017–2019 | 1 | 23 | 64 | 10:13 | n/a | 59.6 | 52 | n/a | n/a |
Jumeau (2018) | Canada | retrospective data analysis | 2010–2016 | 1 | 21 | 69 | 07:13 | n/a | 52.0 | 38 | 0 | 37.50 |
Liauw (2020) | USA | prospective clinical trial phase I/II | 2010–2016 | 1 | 15 | 61 | 06:09 | 1 | n/a | 100 | n/a | 76.95 |
Macchia (2012) | Italy | case series | n/a | 1 | 16 | 61 | 11:05 | 2 | 56.0 | 94 | 56 | 32.6 |
Ryan (2018) | USA | retrospective data analysis | 2010–2016 | 1 | 29 | 74 | 11:18 | 2 | 76.0 | 76 | 0 | 36.40 |
Shen (2010) | China | prospective observational trial | 2009–2010 | 1 | 20 | 54 | 14:06 | 2 | 65.0 | n/a | n/a | n/a |
Tozzi (2013) | Italy | prospective clinical trial | 2010–2011 | 1 | 30 | 67 | 20:10 | 2 | 70.0 | 100 | 0 | 62.69 |